Last week, Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences, spoke at the 10th Conference of the International Society for Affective Disorders (ISAD19), an important gathering of the European affective disorders expert community. This year’s programme addressed fundamental, clinical and translational issues in affective disorders, with experts from around the world travelling to London to share the latest scientific research developments.
ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
JOIN THE ATAI #INSIGHTNETWORK